GEXVal CEO Featured in JBA’s "Bioscience and Industry" Magazine

株式會社GEXVal
August 25, 2026

JBA’s B&I Magazine Features Interview with GEXVal CEO
Special Feature: "Dawn of Bio: Startups Are Heating Up!"

GEXVal Inc. (President and CEO: Juran Kato, PhD; Headquarters: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that an interview with Dr. Kato will be featured in "Bioscience and Industry (B&I)," a magazine published by the Japan Bioindustry Association (JBA), under the special feature "Dawn of Bio: Startups Are Heating Up!"

[Background]
Patients with rare diseases often wait years for a diagnosis, and even once a cause is identified, treatment options frequently remain limited. Guided by its mission — Treatment Reaches the Unreached — GEXVal is committed to developing therapies that address rare diseases and other conditions with unmet medical needs. This feature introduces the work of Japan-based biotech ventures, offering an opportunity to share GEXVal's approach to drug discovery for rare diseases and to highlight the broader potential of Japan’s biotech startups.

**Publication Details**

[Comment from President and CEO / Chief Scientific Officer Juran Kato, PhD]
"I’m grateful for this opportunity to share our work as part of JBA's feature series. I reflected on the path we’ve taken and shared my outlook for the future, driven by our commitment to bringing treatments to patients and families who live with rare diseases."

[About B&I]
"Bioscience and Industry (B&I)" is a bimonthly publication launched in 1988 by the Japan Bioindustry Association (JBA), a general incorporated foundation. The magazine covers a broad range of topics spanning basic research through industrial applications in the biosciences, and is read by researchers, industry professionals, and policymakers across fields such as pharmaceuticals, healthcare, food, chemicals, and the environment.

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com